BCABBioAtla, Inc.vs its industry peers
A metric-by-metric comparison of BioAtla, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCABThis | — | 0.1x#2 | — | — | — | -14.6%#4 | -19768.3%#4 | — | — | — | -95.4%#5 | — |
| CELZ | $6M#1 | — | 0.7x#2 | 960.9x#5 | -45.5%#3 | -9.1%#3 | -102380.2%#6 | -69.3%#2 | -66.1%#1 | 3#2 | -75.0%#2 | — |
| ZIVO | $5M#2 | — | — | 31.3x#3 | 468.6%#1 | -72.1%#5 | -8498.9%#2 | — | — | — | — | — |
| CLDI | $3M#4 | 0.0x#1 | 1.0x#3 | 68.9x#4 | — | 10.1%#2 | -44977.8%#5 | -635.4%#3 | — | — | -95.3%#4 | — |
| SABSW | $3M#5 | 0.1x#3 | 0.0x#1 | — | -100.0%#5 | 138.9%#1 | — | 6.2%#1 | — | — | — | — |
| SCLXW | $1M#6 | — | — | 0.0x#1 | -46.5%#4 | -413.8%#6 | -1143.7%#1 | — | — | 4#1 | 438.3%#1 | — |
| VIVS | $4M#3 | — | — | 31.2x#2 | -9.0%#2 | -456.4%#7 | -8768.7%#3 | — | — | — | -94.2%#3 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice